{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:28:34Z","timestamp":1791188914384,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T00:00:00Z","timestamp":1441324800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13063-015-0898-4","type":"journal-article","created":{"date-parts":[[2015,9,4]],"date-time":"2015-09-04T09:52:38Z","timestamp":1441360358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":54,"title":["Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"16","author":[{"name":"on behalf of the APACHE-AF investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen M.","family":"van Nieuwenhuizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. Bart","family":"van der Worp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ale","family":"Algra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Jaap","family":"Kappelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel J. E.","family":"Rinkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle C.","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger E. G.","family":"Schutgens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharina J. M.","family":"Klijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,4]]},"reference":[{"key":"898_CR1","volume-title":"Volksgezond Toekomst Verkenning, Natl Kompas Volksgezond","author":"M Poos","year":"2013","unstructured":"Poos M, Gommer A. Aan welke ziekten gaan veel levensjaren verloren? In: Volksgezond Toekomst Verkenning, Natl Kompas Volksgezond. Bilthoven: RIVM; 2013."},{"key":"898_CR2","unstructured":"Kosten van Ziekten 2011. http:\/\/www.kostenvanziekten.nl . Accessed 12 February 2015."},{"key":"898_CR3","volume-title":"Hoe vaak komt een beroerte voor en hoeveel mensen sterven eraan? In: Volksgezond Toekomst Verkenning, Natl Kompas Volksgezond","author":"I Vaartjes","year":"2011","unstructured":"Vaartjes I, Bots ML, Poos M. Hoe vaak komt een beroerte voor en hoeveel mensen sterven eraan? In: Volksgezond Toekomst Verkenning, Natl Kompas Volksgezond. Bilthoven: RIVM; 2011."},{"key":"898_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/hs1201.100209","volume":"32","author":"PL Kolominsky-Rabas","year":"2001","unstructured":"Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU. Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes: a population-based study. Stroke. 2001;32:2735\u201340.","journal-title":"Stroke"},{"key":"898_CR5","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/jnnp.2008.150318","volume":"79","author":"Y Bejot","year":"2008","unstructured":"Bejot Y, Caillier M, Ben Salem D, Couvreur G, Rouaud O, Osseby G-V, et al. Ischaemic stroke subtypes and associated risk factors: a French population based study. J Neurol Neurosurg Psychiatry. 2008;79:1344\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"898_CR6","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1001\/archinte.1994.00420130036007","volume":"154","author":"A Laupacis","year":"1994","unstructured":"Laupacis A, Boysen G, Connolly SJ, Ezekowitz MD, Hart RG, James K, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:1449.","journal-title":"Arch Intern Med"},{"key":"898_CR7","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest"},{"key":"898_CR8","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1161\/STROKEAHA.110.590257","volume":"41","author":"GYH Lip","year":"2010","unstructured":"Lip GYH, Frison L, Halperin JL, Lane DA. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41:2731\u20138.","journal-title":"Stroke"},{"issue":"2 Suppl","key":"898_CR9","doi-asserted-by":"publisher","first-page":"e531S","DOI":"10.1378\/chest.11-2304","volume":"141","author":"JJ You","year":"2012","unstructured":"You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, et al. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e531S\u201375S.","journal-title":"Chest"},{"key":"898_CR10","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","volume":"31","author":"AJ Camm","year":"2010","unstructured":"Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369\u2013429.","journal-title":"Eur Heart J"},{"issue":"6 Suppl","key":"898_CR11","doi-asserted-by":"publisher","first-page":"257S","DOI":"10.1378\/chest.08-0674","volume":"133","author":"S Schulman","year":"2008","unstructured":"Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):257S\u201398S.","journal-title":"Chest"},{"key":"898_CR12","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1055\/s-0030-1268866","volume":"30","author":"ML Flaherty","year":"2010","unstructured":"Flaherty ML. Anticoagulant-associated intracerebral hemorrhage. Semin Neurol. 2010;30:565\u201372.","journal-title":"Semin Neurol"},{"key":"898_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.3949\/ccjm.77a.10018","volume":"77","author":"JN Goldstein","year":"2010","unstructured":"Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage? Cleve Clin J Med. 2010;77:791\u20139.","journal-title":"Cleve Clin J Med"},{"key":"898_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1161\/STROKEAHA.113.003003","volume":"45","author":"AMR Schols","year":"2014","unstructured":"Schols AMR, Schreuder FHBM, van Raak EPM, Schreuder THCML, Rooyer FA, van Oostenbrugge RJ, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke. 2014;45:268\u201370.","journal-title":"Stroke"},{"key":"898_CR15","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1161\/STROKEAHA.111.630731","volume":"43","author":"MC Fang","year":"2012","unstructured":"Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. Stroke. 2012;43:1795\u20139.","journal-title":"Stroke"},{"key":"898_CR16","doi-asserted-by":"crossref","unstructured":"Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005:CD001925.","DOI":"10.1002\/14651858.CD001925.pub2"},{"key":"898_CR17","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1001\/jama.2012.5034","volume":"307","author":"G Berardis De","year":"2012","unstructured":"De Berardis G, Lucisano G, D\u2019Ettorre A, Pellegrini F, Lepore V, Tognoni G, et al. Association of aspirin use with major bleeding in patients with and without diabetes. JAMA. 2012;307:2286\u201394.","journal-title":"JAMA"},{"key":"898_CR18","doi-asserted-by":"publisher","first-page":"3661","DOI":"10.1161\/STROKEAHA.111.621797","volume":"42","author":"T Steiner","year":"2011","unstructured":"Steiner T. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: yes. Stroke. 2011;42:3661\u20132.","journal-title":"Stroke"},{"key":"898_CR19","doi-asserted-by":"publisher","first-page":"3663","DOI":"10.1161\/STROKEAHA.111.621813","volume":"42","author":"S Schulman","year":"2011","unstructured":"Schulman S. Resumption of oral anticoagulation after warfarin-associated intracerebral hemorrhage: no. Stroke. 2011;42:3663\u20134.","journal-title":"Stroke"},{"key":"898_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/j.1755-5922.2009.00118.x","volume":"28","author":"RWV Flynn","year":"2010","unstructured":"Flynn RWV, MacDonald TM, Murray GD, Doney ASF. Systematic review of observational research studying the long-term use of antithrombotic medicines following intracerebral hemorrhage. Cardiovasc Ther. 2010;28:177\u201384.","journal-title":"Cardiovasc Ther"},{"key":"898_CR21","doi-asserted-by":"publisher","unstructured":"Nielsen PB, Larsen TB, Gorst-Rasmussen A, Skj\u00f8th F, Rasmussen LH, Lip GYH. Intracranial haemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest. 2014;:1\u201330. doi: 10.1378\/chest.14-2099 .","DOI":"10.1378\/chest.14-2099"},{"key":"898_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s004150050565","volume":"247","author":"M Bertram","year":"2000","unstructured":"Bertram M, Bonsanto M, Hacke W, Schwab S. Managing the therapeutic dilemma: patients with spontaneous intracerebral hemorrhage and urgent need for anticoagulation. J Neurol. 2000;247:209\u201314.","journal-title":"J Neurol"},{"key":"898_CR23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1001\/archneur.65.10.1313","volume":"65","author":"DO Claassen","year":"2008","unstructured":"Claassen DO, Kazemi N, Zubkov AY, Wijdicks EFM, Rabinstein AA. Restarting anticoagulation therapy after warfarin-associated intracerebral hemorrhage. Arch Neurol. 2008;65:1313\u20138.","journal-title":"Arch Neurol"},{"key":"898_CR24","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1161\/STROKEAHA.110.593087","volume":"41","author":"A Majeed","year":"2010","unstructured":"Majeed A, Kim Y-K, Roberts RS, Holmstr\u00f6m M, Schulman S. Optimal timing of resumption of warfarin after intracranial hemorrhage. Stroke. 2010;41:2860\u20136.","journal-title":"Stroke"},{"key":"898_CR25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1159\/000351151","volume":"36","author":"CS Gathier","year":"2013","unstructured":"Gathier CS, Algra A, Rinkel GJE, van der Worp HB. Long-term outcome after anticoagulation-associated intracerebral haemorrhage with or without restarting antithrombotic therapy. Cerebrovasc Dis. 2013;36:33\u20137.","journal-title":"Cerebrovasc Dis"},{"key":"898_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cjca.2011.10.002","volume":"28","author":"D Yung","year":"2012","unstructured":"Yung D, Kapral MK, Asllani E, Fang J, Lee DS. Reinitiation of anticoagulation after warfarin-associated intracranial hemorrhage and mortality risk: the Best Practice for Reinitiating Anticoagulation Therapy After Intracranial Bleeding (BRAIN) study. Can J Cardiol. 2012;28:33\u20139.","journal-title":"Can J Cardiol"},{"key":"898_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1160\/TH11-06-0439","volume":"107","author":"B-H Chong","year":"2012","unstructured":"Chong B-H, Chan K-H, Pong V, Lau K-K, Chan Y-H, Zuo M-L, et al. Use of aspirin in Chinese after recovery from primary intracranial haemorrhage. Thromb Haemost. 2012;107:241\u20137.","journal-title":"Thromb Haemost"},{"key":"898_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1212\/01.wnl.0000194267.09060.77","volume":"66","author":"A Viswanathan","year":"2006","unstructured":"Viswanathan A, Rakich SM, Engel C, Snider R, Rosand J, Greenberg SM, et al. Antiplatelet use after intracerebral hemorrhage. Neurology. 2006;66:206\u20139.","journal-title":"Neurology"},{"key":"898_CR29","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/WNL.0b013e3181eee40f","volume":"75","author":"A Biffi","year":"2010","unstructured":"Biffi A, Halpin A, Towfighi A, Gilson A, Busl K, Rost N, et al. Aspirin and recurrent intracerebral hemorrhage in cerebral amyloid angiopathy. Neurology. 2010;75:693\u20138.","journal-title":"Neurology"},{"key":"898_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000094831","volume":"22","author":"T Steiner","year":"2006","unstructured":"Steiner T, Kaste M, Katse M, Forsting M, Mendelow D, Kwiecinski H, et al. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22:294\u2013316.","journal-title":"Cerebrovasc Dis"},{"key":"898_CR31","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","volume":"41","author":"LB Morgenstern","year":"2010","unstructured":"Morgenstern LB, Hemphill JC, Anderson C, Becker K, Broderick JP, Connolly ES, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2010;41:2108\u201329.","journal-title":"Stroke"},{"key":"898_CR32","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1161\/STROKEAHA.114.006202","volume":"45","author":"M Pasquini","year":"2014","unstructured":"Pasquini M, Charidimou A, van Asch CJJ, Baharoglu MI, Samarasekera N, Werring DJ, et al. Variation in restarting antithrombotic drugs at hospital discharge after intracerebral hemorrhage. Stroke. 2014;45:2643\u20138.","journal-title":"Stroke"},{"key":"898_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981\u201392.","journal-title":"N Engl J Med"},{"key":"898_CR34","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1161\/CIRCULATIONAHA.112.142158","volume":"127","author":"L Wallentin","year":"2013","unstructured":"Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166\u201376.","journal-title":"Circulation"},{"key":"898_CR35","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener H-C, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806\u201317.","journal-title":"N Engl J Med"},{"key":"898_CR36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883\u201391.","journal-title":"N Engl J Med"},{"key":"898_CR37","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093\u2013104.","journal-title":"N Engl J Med"},{"key":"898_CR38","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139\u201351.","journal-title":"N Engl J Med"},{"key":"898_CR39","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955\u201362.","journal-title":"Lancet"},{"key":"898_CR40","first-page":"1486","volume":"70","author":"S Chatterjee","year":"2013","unstructured":"Chatterjee S, Sardar P, Biondi-Zoccai G, Kumbhani DJ. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation. JAMA Neurol. 2013;70:1486\u201390.","journal-title":"JAMA Neurol"},{"key":"898_CR41","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.1161\/STROKEAHA.111.631689","volume":"42","author":"C Molina","year":"2011","unstructured":"Molina C, Selim MH. The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears. Stroke. 2011;42:3665\u20136.","journal-title":"Stroke"},{"key":"898_CR42","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1160\/TH13-09-0741","volume":"111","author":"GJ Hankey","year":"2014","unstructured":"Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost. 2014;111:808\u201316.","journal-title":"Thromb Haemost"},{"key":"898_CR43","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/j.1538-7836.2010.03882.x","volume":"8","author":"GWJ Hawryluk","year":"2010","unstructured":"Hawryluk GWJ, Austin JW, Furlan JC, Lee JB, O\u2019Kelly C, Fehlings MG. Management of anticoagulation following central nervous system hemorrhage in patients with high thromboembolic risk. J Thromb Haemost. 2010;8:1500\u20138.","journal-title":"J Thromb Haemost"},{"key":"898_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08037059209077502","volume":"1","author":"L Hansson","year":"1992","unstructured":"Hansson L, Hedner T, Dahl\u00f6f B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective Randomized Open Blinded End-Point. Blood Press. 1992;1:113\u20139.","journal-title":"Blood Press"},{"key":"898_CR45","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC Swieten Van","year":"1988","unstructured":"Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604\u20137.","journal-title":"Stroke"},{"key":"898_CR46","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1161\/01.STR.20.7.864","volume":"20","author":"T Brott","year":"1989","unstructured":"Brott T, Adams HP, Olinger CP, Marler JR, Barsan WG, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989;20:864\u201370.","journal-title":"Stroke"},{"key":"898_CR47","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest"},{"key":"898_CR48","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1017\/S003329170002691X","volume":"24","author":"AF Jorm","year":"2009","unstructured":"Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 2009;24:145.","journal-title":"Psychol Med"},{"key":"898_CR49","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1751-7176.2008.07572.x","volume":"10","author":"DE Morisky","year":"2008","unstructured":"Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich). 2008;10:348\u201354.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"898_CR50","unstructured":"Nederlandse Federatie van Universitair Medische Centra. Kwaliteitsborging Mensgebonden Onderzoek 2.0. Nederlandse Federatie van Universitair Medische Centra; 2012."},{"key":"898_CR51","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","volume":"60","author":"K Thygesen","year":"2012","unstructured":"Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581\u201398.","journal-title":"J Am Coll Cardiol"},{"key":"898_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"898_CR53","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ahj.2009.07.035","volume":"159","author":"RD Lopes","year":"2010","unstructured":"Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010;159:331\u20139.","journal-title":"Am Heart J"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-015-0898-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T14:58:24Z","timestamp":1498229904000},"score":1,"resource":{"primary":{"URL":"http:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-015-0898-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,4]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["898"],"URL":"https:\/\/doi.org\/10.1186\/s13063-015-0898-4","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,4]]},"article-number":"393"}}